After the Overdose: The 30 Days That Decide Survival

Two studies landed on May 7. They tell the same story from opposite ends. One — from the Centre for Addiction and Mental Health and ICES in Toronto — quantifies how dangerous the weeks after a non-fatal overdose really are. The other, from a 42-expert Delphi panel in JAMA Network Open, tells hospitals what to do about it.

Together they reframe the highest-leverage intervention in addiction medicine: not the first dose of treatment, but the bridge between the emergency department and whatever comes next.

What the new mortality numbers say

The CAMH/ICES study followed people in Ontario who survived a non-fatal opioid overdose and presented to an emergency department. Within twelve months, 9% had died and 21% had at least one more overdose. Pre-fentanyl-era estimates placed mortality between 5.3% and 5.5%. The risk is not constant — lead author Robert Kleinman noted it spikes in the first 7 to 30 days after discharge.

That number — 9% one-year mortality — is on par with several common cancers in the same age range. It is the closest thing addiction medicine has to a known case-fatality rate for survivors of an acute event. And the spike at days 7–30 means the window where intervention matters most is short, predictable, and almost entirely outside the hospital.

What the Delphi panel landed on

The same week, JAMA Network Open published a consensus from 42 hospital-based addiction-medicine clinicians. They used the Delphi method — multiple structured rounds of voting on hypothetical patient cases — to build agreement on hospital-initiated MOUD protocols that have moved fast in the last two years but lacked formal consensus. The published guidance covers four practices:

1. Rapid methadone initiation — for patients whose tolerance argues against starting bup
2. High-dose buprenorphine initiation — moving past the cautious 4–8 mg start
3. Low-dose (“micro-induction”) bup — for patients still using fentanyl who can’t tolerate withdrawal
4. Long-acting injectable formulations before discharge — so the bridge doesn’t depend on the patient filling a prescription on day three

These are not new ideas. They are what experienced inpatient addiction services have been doing. The study’s contribution is that 42 experts now formally agree, in a peer-reviewed journal, on what “appropriate” looks like — which is what hospital administrators, payers, and credentialing bodies need before adoption stops being uneven.

Why this matters now

The two papers connect directly. CAMH defines the size and shape of the post-discharge mortality window. The Yale Delphi gives clinical teams a defensible playbook for the in-hospital intervention that closes it. The bridge between them is the part the field has historically gotten wrong: the handoff from the hospital to a community provider who will see the patient within seven days.

Most U.S. hospitals do not have an addiction-medicine consult service. Most discharged patients are handed a referral list and asked to navigate it themselves, often within hours of being medically stabilized. The Delphi consensus implicitly assumes that a community MOUD provider exists, has capacity, accepts the patient’s insurance, and can see them quickly. In Maricopa County and most of Arizona, two of those four assumptions hold reliably.

That gap is where overdose survivors die.

What’s also reshaping the picture

FDA’s May 7 Synthetic Soup webinar added a sharper edge: the supply that survivors return to is changing faster than naloxone can keep up with. UNC’s Dr. Nabarun Dasgupta presented data on novel adulterants — nitazenes, cychlorphine, BTPMS, medetomidine — that are detected at a roughly monthly cadence. Some are more potent than fentanyl. Several do not respond predictably to naloxone reversal. The patient discharged on day one is going home to a different chemical environment than the one they overdosed on.

Nabarun Dasgupta presented data on novel adulterants — nitazenes, cychlorphine, BTPMS, medetomidine — that are detected at a roughly monthly cadence.

That changes what “successful discharge” means. A naloxone kit at the door is necessary and not enough.

Why this matters for people in recovery

If you or someone you love has just survived an overdose, the next month is the single most important window — and it is the window that hospital systems most reliably fail. Three things to ask before discharge: (1) “Can MOUD be started here, today, before I leave?” (2) “Do you have a follow-up appointment booked within seven days?” (3) “Can I leave with an extended-release injectable rather than a prescription I have to fill?” If the answer to any of those is no, ask why. The CAMH numbers are the reason.

Rize is building tools that surface answers to these questions in real time — which Arizona facilities can start MOUD on the day of an ED visit, which can do same-week intake, which accept your insurance. If you need help finding one tonight, our matching tool is the fastest path. If someone you love is in crisis, call or text 988.

---

Sources: CAMH · Yale Medicine / JAMA Network Open · FDA Synthetic Soup webinar 5/7/26